Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer-Reference-Cited by-同舟云学术

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

Published:2018-02 Issue:2 Volume:29 Page:424-430
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

de Boer S.M.,Wortman B.G.,Bosse T.,Powell M.E.,Singh N.,Hollema H.,Wilson G.,Chowdhury M.N.,Mileshkin L.,Pyman J.,Katsaros D.,Carinelli S.,Fyles A.,McLachlin C.M.,Haie-Meder C.,Duvillard P.,Nout R.A.,Verhoeven-Adema K.W.,Putter H.,Creutzberg C.L.,Smit V.T.H.B.M.

Funder

Dutch Cancer Society

Cancer Research UK

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/2/424/23980242/mdx753.pdf

Reference26 articles.

1. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma;Creutzberg;Lancet,2000

2. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study;Keys;Gynecol Oncol,2004